Search results
Sep 9, 2022 · The risk of prostate cancer rises rapidly after age 50, and according to analytic studies, about 6 in 10 cases of prostate cancer are found in men older than 65 who have lower overall survival. As a result, it is highly recommended to encourage older men (over 60) to get prostate-specific antigen (PSA) test screening frequently ( Vickers et al., 2010 ; Jayadevappa et al., 2011 ).
- 10.3389/fcell.2022.991330
- 2022
- Front Cell Dev Biol. 2022; 10: 991330.
Dec 1, 2023 · Introduction. The evolution of prostate cancer (PC) treatment has been a success story. In the 1960s, 50%−60% of Northern European men diagnosed for PC died of it within 5 years, and the relative survival rate was still well below 70% in the 1980s. 1,2 In 2016, the 5-year relative survival rate was 93.6% in Sweden and 92.4% in Finland. 2,3 In this paper, we will discuss how this remarkable achievement was established by describing key moments in PC discovery and treatment throughout history.
- 10.1177/20503121231216837
- 2023
- SAGE Open Med. 2023; 11: 20503121231216837.
Sep 5, 2022 · Analyses of case-control, twin, and family studies have concluded that prostate cancer risk may be a result of heritable factors. Research has shown specific gene mutations in hereditary prostate cancer and has reported that patients with these mutations have an increased risk of the disease . In the genetic evaluation of inheritance ...
Jul 31, 2018 · Extensive research in the field of prostate cancer has resulted in important discoveries that have influenced our understanding of this disease and its management (Fig. 1).Distinguishing the ...
- Niranjan J Sathianathen, Badrinath R Konety, Juanita Crook, Fred Saad, Nathan L Lawrentschuk
- 2018
Aug 6, 2021 · The management of prostate cancer continues to evolve rapidly, with substantial advances being made in understanding the genomic landscape and biology underpinning both primary and metastatic prostate cancer. Similarly, the emergence of more sensitive imaging methods has improved diagnostic and staging accuracy and refined surveillance strategies. These advances have introduced personalised therapeutics to clinical practice, with treatments targeting genomic alterations in DNA repair ...
Advances in Prostate Cancer Research. Nanoparticles are tested as a means to deliver drugs to prostate cancer cells. NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat prostate cancer. Most men diagnosed with prostate cancer will live a long time, but challenges remain in choosing the best ...
People also ask
How has research impacted our understanding of prostate cancer?
How can research help patients with prostate cancer?
Why do we want a future with prostate cancer?
Can new treatments improve the lives of patients with prostate cancer?
We've invested over £75 million in research over the last 25 years which has started to make a significant difference, but there is still so much to do. You can help us fund research to stop prostate cancer killing men by making a donation today. Find out about the impact of our research into prostate cancer and what we’ve achieved.
